These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30527753)

  • 1. Liposomes with cyclic RGD peptide motif triggers acute immune response in mice.
    Wang X; Wang H; Jiang K; Zhang Y; Zhan C; Ying M; Zhang M; Lu L; Wang R; Wang S; Burgess DJ; Wang H; Lu W
    J Control Release; 2019 Jan; 293():201-214. PubMed ID: 30527753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Influencing the Immunogenicity and Immunotoxicity of Cyclic RGD Peptide-Modified Nanodrug Delivery Systems.
    Wang X; Meng N; Wang S; Lu L; Wang H; Zhan C; Burgess DJ; Lu W
    Mol Pharm; 2020 Sep; 17(9):3281-3290. PubMed ID: 32786957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
    Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
    Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
    Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
    Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer.
    Zhao H; Wang JC; Sun QS; Luo CL; Zhang Q
    J Drug Target; 2009 Jan; 17(1):10-8. PubMed ID: 19016068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
    Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
    J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of a novel adapter lipid derivative for preparation of cyclic peptide-modified PEGylated liposomes: Application of cyclic RGD peptide.
    Kato N; Sato T; Fuchigami Y; Suga T; Geng L; Tsurumaru M; Hagimori M; Mukai H; Kawakami S
    Eur J Pharm Sci; 2022 Sep; 176():106239. PubMed ID: 35714942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomes modified with cyclic RGD peptide for tumor targeting.
    Dubey PK; Mishra V; Jain S; Mahor S; Vyas SP
    J Drug Target; 2004 Jun; 12(5):257-64. PubMed ID: 15512776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent.
    Zhang X; Chen X
    Appl Radiat Isot; 2007 Jan; 65(1):70-8. PubMed ID: 17011200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB.
    Chen C; Duan Z; Yuan Y; Li R; Pang L; Liang J; Xu X; Wang J
    ACS Appl Mater Interfaces; 2017 Feb; 9(7):5864-5873. PubMed ID: 28128553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy: stability, therapeutic efficacy, and safety studies in mice.
    Jin ZH; Furukawa T; Ohya T; Degardin M; Sugyo A; Tsuji AB; Fujibayashi Y; Zhang MR; Higashi T; Boturyn D; Dumy P; Saga T
    Nucl Med Commun; 2017 Apr; 38(4):347-355. PubMed ID: 28291159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide.
    Zhang Q; Lu L; Zhang L; Shi K; Cun X; Yang Y; Liu Y; Gao H; He Q
    Sci Rep; 2016 Feb; 6():19800. PubMed ID: 26842655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-targeting liposomes with active recognition of GLUT
    Pu Y; Zhang H; Peng Y; Fu Q; Yue Q; Zhao Y; Guo L; Wu Y
    Eur J Med Chem; 2019 Dec; 183():111720. PubMed ID: 31553933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
    Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
    Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy.
    Li C; Shen J; Wei X; Xie C; Lu W
    J Drug Target; 2012 Apr; 20(3):264-71. PubMed ID: 22233211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
    Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
    Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
    Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
    J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.